Emily Barry1, Ilir Agalliu2,3, Richard Maiman3, Evan Shreck3, Evan Kovac3, Ahmed Aboumohamed3, Alexander Sankin3. 1. Albert Einstein College of Medicine; Bronx, NY. 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine; Bronx, NY. 3. Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY.
Abstract
INTRODUCTION: We sought to determine if outcomes of Bacillus Calmette-Guerin (BCG) therapy in patients with non-muscle-invasive bladder cancer (NMIBC) vary by race. METHODS: A retrospective chart review was conducted on 149 patients treated with BCG for intermediate- and high-risk NMIBC between 2001 and 2018, and who were followed up for cancer recurrence through March 2019.The primary outcomes were disease-free survival (DFS), low-grade disease-free survival (LGDFS), high-grade disease-free survival (HGDFS), and progression-free survival (PFS) at five years. Kaplan-Meier survival curves stratified by race (African American vs non-African American) were analyzed for all the above outcomes and multivariate Cox regression analyses were also performed to compare recurrence differences by race, after adjusting for age, sex, initial stage and grade. RESULTS: Of the 149 patients, 37.6% were Caucasian, 24.8% were African American, 26.8% were Hispanic, and 10.7% were of other/unknown race. Disease stage at initial presentation was 65.1% Ta, 34.9% T1, and 18.1% CIS. African American patients (N=37) did not have evidence for worse outcomes compared to non-African American patients when considering DFS (54.1% vs. 65.7%, p = 0.202), HGDFS (58.8% vs. 71.7%, p = 0.158), and PFS (83.8% vs. 92.6%, p = 0.117) at five years. Multivariate analysis did not reveal statistically significant racial differences in recurrence or progression. CONCLUSIONS: African Americans with NMIBC did not have worse disease recurrence and progression after receiving intravesical BCG treatment. Although there did appear to be a trend towards worse oncologic outcomes in African Americans, larger studies are needed to validate this finding.
INTRODUCTION: We sought to determine if outcomes of Bacillus Calmette-Guerin (BCG) therapy in patients with non-muscle-invasive bladder cancer (NMIBC) vary by race. METHODS: A retrospective chart review was conducted on 149 patients treated with BCG for intermediate- and high-risk NMIBC between 2001 and 2018, and who were followed up for cancer recurrence through March 2019.The primary outcomes were disease-free survival (DFS), low-grade disease-free survival (LGDFS), high-grade disease-free survival (HGDFS), and progression-free survival (PFS) at five years. Kaplan-Meier survival curves stratified by race (African American vs non-African American) were analyzed for all the above outcomes and multivariate Cox regression analyses were also performed to compare recurrence differences by race, after adjusting for age, sex, initial stage and grade. RESULTS: Of the 149 patients, 37.6% were Caucasian, 24.8% were African American, 26.8% were Hispanic, and 10.7% were of other/unknown race. Disease stage at initial presentation was 65.1% Ta, 34.9% T1, and 18.1% CIS. African American patients (N=37) did not have evidence for worse outcomes compared to non-African American patients when considering DFS (54.1% vs. 65.7%, p = 0.202), HGDFS (58.8% vs. 71.7%, p = 0.158), and PFS (83.8% vs. 92.6%, p = 0.117) at five years. Multivariate analysis did not reveal statistically significant racial differences in recurrence or progression. CONCLUSIONS: African Americans with NMIBC did not have worse disease recurrence and progression after receiving intravesical BCG treatment. Although there did appear to be a trend towards worse oncologic outcomes in African Americans, larger studies are needed to validate this finding.
Authors: G R Prout; M N Wesley; R S Greenberg; V W Chen; C C Brown; A W Miller; R S Weinstein; S J Robboy; M A Haynes; R S Blacklow; B K Edwards Journal: Cancer Date: 2000-09-15 Impact factor: 6.860
Authors: Peter L Rady; Reuben Matalon; James Grady; Eric M Smith; S David Hudnall; Leonard H Kellner; Harold Nitowsky; Stephen K Tyring; Thomas K Hughes Journal: Genet Test Date: 2004
Authors: George R Prout; Margaret N Wesley; Peter G McCarron; Vivien W Chen; Raymond S Greenberg; Robert M Mayberry; Brenda K Edwards Journal: Cancer Date: 2004-02-01 Impact factor: 6.860
Authors: Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup Journal: Eur Urol Date: 2019-08-20 Impact factor: 20.096
Authors: P Nahid; L G Jarlsberg; M Kato-Maeda; M R Segal; D H Osmond; S Gagneux; K Dobos; M Gold; P C Hopewell; D M Lewinsohn Journal: PLoS One Date: 2018-05-22 Impact factor: 3.240
Authors: Tomas Thiel; Charlotta Ryk; Lotta Renström-Koskela; Gunnar Steineck; Martin C Schumacher; N Peter Wiklund; Petra J de Verdier Journal: World J Urol Date: 2018-06-15 Impact factor: 4.226